Brand-Name Generic Deals Face End of the Line: Congress Likely to Ban Exclusion Payments

類似資料

• Brand Name Versus Generic
  著者:: Brovar, Alan
  出版事項: (1981)
• Congress Enters Contentious Debate on Biosimilar Naming: Bill Provision Sides With Brand-Name Companies Over USP
  著者:: Barlas, Stephen
  出版事項: (2016)
• Congress Agrees on the Need For Comparativeness Research: But Funding Will Be a Problem
  著者:: Barlas, Stephen
  出版事項: (2008)
• FDA Science Base Badly Eroded: But Will Congress Provide Urgent New Funding?
  著者:: Barlas, Stephen
  出版事項: (2008)
• Senate May Compromise on ‘Biosimilars’: But Length of Market Exclusivity Poses a Stumbling Block
  著者:: Barlas, Stephen
  出版事項: (2008)